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Defining the Cardiorenal Syndrome
The simplistic view of cardiorenal syndrome (CRS) is that a relatively normalkidney is dysfunctional because of a diseased heart. Ronco and colleagues offer a
more sophisticated definition of CRS to incorporate the vast array of inter-related
derangements and to stress the bidirectional nature of the interaction. Five subtypes of
CRS are defined. Understanding the pathophysiological mechanisms underlying each
subtype can help to provide a rationale for management strategies. See page 1527.
See figure.
Page 1543
Clinical Trial
Tolvaptan Reduces Wedge Pressure and Increases Urine Output
Udelson and colleagues randomized almost 200 patients with heart failure (HF)and elevated filling pressures to a single dose of tolvaptan or placebo and then
monitored their hemodynamics for up to12h.Tolvaptan reducedpulmonary capillary
wedge pressure, right atrial pressure, and pulmonary artery pressure, and increased
urine output compared to placebo. These data provide mechanistic support for the
symptomatic improvementsnotedwith tolvaptan inpatientswithdecompensatedHF.
See page 1540. See figure.
Page 1551
Lipid Disorders
Mutated LDLR Common in Patients Thought to Have FCH
Civeira and colleagues used a microarray that analyzes for 203 mutations in thelow-density lipoprotein receptor (LDLR) gene and 4 defects in the apoplipopro-
teinE (APOE) gene to investigate unrelated patientswith a clinical diagnosis of familial
combined hypercholesterolemia (FCH). Approximately 20% of these patients had a
mutation, and a total of 22 different mutations were found. Those with a mutation
were more likely to have apolipoprotein B (apoB) levels335 mg/dl or low-density
lipoprotein (LDL) 185 mg/dl. Significant elevations in apoB or LDL, even if
triglycerides are also elevated,may indicate amutation inLDLand a diagnosis of familial
hypercholesterolemia (FH), rather than FCH. See pages 1546 and 1554. See
figure.
(continued on page A-34)
(continued) A-34Antiplatelet Therapy
CCBs May Reduce the Efficacy of Clopidogrel
Clopidogrel is a pro-drug that requires hepatic bioactivation by the cytochromeP450 isoform 3A4. Most calcium-channel blockers (CCBs) are metabolized by
the same enzyme to inactive metabolites. Siller-Matula and colleagues report that the
platelet reactivity index was higher, that is, less inhibited, in patients who were taking
both a CCB and clopidogrel compared to those only taking a clopidogrel blocker.
Coadministration of CCBs and clopidogrel may result in decreased efficacy of clopi-
dogrel. See pages 1557 and 1564. See figure.
Page 1570
Heart Rhythm Disorders
Males Are More Symptomatically Affected by Brugada Syndrome
Benito and colleagues analyzed 384 patients with Brugada syndrome (approxi-mately two-thirds male) to assess differences in clinical phenotype and prognosis
according to gender. Males presented more frequently with symptoms, were more
likely to have inducible ventricular fibrillation (VF), and were more likely to have
sudden death orVFduring follow-up.However, conduction parameters and corrected
QT interval after exposure to sodium-channel blockers increased more in females.
These results highlight the significant effect of gender on clinical outcomes in patients
with Brugada syndrome. See page 1567. See figure.
Page 1577
Cardiac Imaging
CMR Can Quantify Diffuse Myocardial Fibrosis
Regional myocardial fibrosis can be identified with delayed contrast enhancementon cardiacmagnetic resonance imaging (deCMR).However, this technique relies
ondifferences between scarred andnormalmyocardium, limiting its ability to diagnose
diffuse processes. Iles and colleagues developed a technique to calculate a global
post-contrast myocardial T1 time as an index of diffuse fibrosis. This technique was
validated in a series of experiments including comparisons to endomyocardial biopsy
specimens and echocardiographic measurements of myocardial stiffness. This tech-
nique appears to be a valid method for identifying diffuse myocardial fibrosis. See
pages 1574 and 1581. See figure.(continued on page A-39)
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Works in Progress
Percutaneous LVAD Restores Cardiac Output More Quickly Than IABP
The Impella LP2.5 is a percutaneously-delivered left ventricular assist device(LVAD) that is placed retrogradely into the left ventricle and pumps blood at up
to 2.5 l/min to the ascending aorta. Seyfarth and colleagues assigned 26 patients with
cardiogenic shock secondary to acute myocardial infarction to either the LVAD or to
an intra-aortic balloon pump (IABP). Those assigned to LVAD had greater improve-
ments in cardiac index andmean arterial pressure. Larger trials will be needed to assess
the impact on clinical outcomes, but this LVAD appears promising for patients with
cardiogenic shock. See page 1584. See figure.
Page 1593
Pre-Clinical Research
Polyelectrolyte Film Treatment May Extend Life of Arterial Conduit Grafts
Kerdjoudj and colleagues have shown that treating arteries that have been de-endothelialized with alternating layers of polyanions and polycations can form a
polyelectrolytemultilayer film (PEM) that is both biocompatible and bioinert. For this
in vivo study, human umbilical arteries were treated with PEM and used as bypass
grafts for rabbit carotids. Follow-up included serial ultrasound evaluations and histo-
logical examination. All PEM-coated conduits were patent and had clean luminal
surfaces at up to 12 weeks of follow-up. This study suggests that human umbilical
arteries treated with PEMmay constitute a useful option for bypassing small arteries.
See page 1589. See figure.
